Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis

Abstract

This meta-analysis provides the evidence that the reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan in patients with essential hypertension. These findings suggest the importance of strict designed randomized controlled trials in determining antihypertensive effects of angiotensin II receptor blockers in clinical practice.

Comparative Effectiveness of Angiotensin II Receptor Blockers in Patients With Hypertension in Japan ― Systematic Review and Network Meta-Analysis ―

“…[29][30][31][32][33][34] We searched PubMed (on November 22, 2019) using the search terms "metaanalysis azilsartan", which identified 2 meta-analyses focusing on the antihypertensive effects of azilsartan. 35,36 The results from the present analysis are consistent with both published meta-analyses. Takagi et al reported a greater reduction in BP with azilsartan therapy than with control therapies including some ARBs in patients with hypertension.…”

“…36 It should be noted that both these meta-analyses included data pertaining to azilsartan medoxomil 80 mg/day, approved in the US, Europe, and other countries. 35,36 It is important to mention that the absolute bioavailability and milligram : milligram dose of the azilsartan tablet formulation is approximately equivalent to half that of the commercial azilsartan medoxomil tablet; thus, azilsartan medoxomil 80 mg is equivalent to azilsartan 40 mg approved in Japan.…”

Effect of Hypoxia-Induced MicroRNA-210 Expression on Cardiovascular Disease and the Underlying Mechanism

“…Furthermore, the upregulation of vascular endothelial growth factor suggested that these effects might be achieved by promoting myocardium angiogenesis. Olmesartan is a member of angiotensin II receptor blockers, which plays an important role in treating hypertension [92]. When evaluating the protective function of olmesartan in a rat model of spontaneously hypertensive myocardial ischemia reperfusion, Lu et al [93] reported that miR-210 is a relatively independent indicator of myocardial protection.…”

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors

“…Полученные в ходе проведенного исследования результаты о преимуществе АЗМ перед другими блокаторами РААС в снижении АД у пациентов с АГ 1-2 согласуются с данными ряда авторов. Мощный гипотензивный эффект АЗМ продемонстрирован ранее в сравнении с рамиприлом [21,22], валсартаном [23], олмесартаном [24,25], кандесартаном [26]. Основой та кого успеха можно считать молекулярную особенность АЗМ -максимальное среди БРА II сродство к рецептору ангиотензина II подтипа 1 [27].…”